000			01533 a2200433 4500
005			20250516044305.0
264		0	_c20110907
008			201109s 0 0 eng d
022			_a1528-0012
024	7		_a10.1053/j.gastro.2011.05.019 _2doi
040			_aNLM _beng _cNLM
100	1		_aSpranger, Joachim
245	0	0	_aGLP-1-based therapies: the dilemma of uncertainty. _h[electronic resource]
260			_bGastroenterology _cJul 2011
300			_a20-3 p. _bdigital
500			_aPublication Type: Editorial; Comment
650	0	4	_aDiabetes Mellitus, Type 2 _xdrug therapy
650	0	4	_aDipeptidyl-Peptidase IV Inhibitors _xadverse effects
650	0	4	_aExenatide
650	0	4	_aGlucagon-Like Peptide-1 Receptor
650	0	4	_aHumans
650	0	4	_aHypoglycemic Agents _xadverse effects
650	0	4	_aPancreatic Neoplasms _xchemically induced
650	0	4	_aPancreatitis _xchemically induced
650	0	4	_aPeptides _xadverse effects
650	0	4	_aPyrazines _xadverse effects
650	0	4	_aReceptors, Glucagon _xagonists
650	0	4	_aRisk Assessment
650	0	4	_aRisk Factors
650	0	4	_aSitagliptin Phosphate
650	0	4	_aThyroid Neoplasms _xchemically induced
650	0	4	_aTriazoles _xadverse effects
650	0	4	_aUncertainty
650	0	4	_aVenoms _xadverse effects
700	1		_aGundert-Remy, Ursula
700	1		_aStammschulte, Thomas
773	0		_tGastroenterology _gvol. 141 _gno. 1 _gp. 20-3
856	4	0	_uhttps://doi.org/10.1053/j.gastro.2011.05.019 _zAvailable from publisher's website
999			_c20976790 _d20976790